Background Cannabinoids modulate fi brogenesis in scleroderma. Ajulemic acid (AjA) is a non-psychoactive synthetic analogue of tetrahydrocannabinol that can bind the peroxisome proliferator-activated receptor-γ (PPAR-γ). Recent evidence suggests a key role for PPAR-γ in fi brogenesis. Objective To determine whether AjA can modulate fi brogenesis in murine models of scleroderma. Material and methods Bleomycin-induced experimental fi brosis was used to assess the antifi brotic effects of AjA in vivo. In addition, the effi cacy of AjA in pre-established fi brosis was analysed in a modifi ed model of bleomycin-induced dermal fi brosis and in mice overexpressing a constitutively active transforming growth factor β (TGFβ) receptor I. Skin fi brosis was evaluated by quantifi cation of skin thickness and hydroxyproline content. As a marker of fi broblast activation, α-smooth muscle actin was examined. To study the direct effect of AjA in collagen neosynthesis, skin fi broblasts from patients with scleroderma were treated with increasing concentrations of AjA. Protein expression of PPAR-γ, and its endogenous ligand 15d-PGJ2, and TGFβ were assessed before and after AjA treatment.
INTRODUCTION
Cannabinoids play key roles in several biological processes, including infl ammation, immunomodulation and vasomotor responses. 1 2 Moreover, the cannabinoid system might also be implicated in the pathogenesis of fi brosis. 3 4 The endocannabinoid system comprises the two specifi c cannabinoid receptors, CB1 and CB2, their endogenous ligands and the machinery dedicated to endocannabinoid EXTENDED REPORT Synthetic cannabinoid ajulemic acid exerts potent antifi brotic effects in experimental models of systemic sclerosis synthesis and degradation. 5 In experimental models of dermal fi brosis, the CB1 and CB2 cannabinoid receptors modulate fi brogenesis by abrogating the underlying infl ammation. 6 7 In addition, cannabinoid agonists limit extracellular matrix (ECM) production by disrupting the transforming growth factor β (TGFβ) cascade, downregulating proliferation and activation of dermal fi broblasts. 8 9 These data argue for a role of cannabinoids in limiting fi brosis, in addition to their anti-infl ammatory and immunomodulatory effects. However, the precise molecular mechanisms remain to be elucidated.
Cannabinoids are not accepted widely as therapeutic agents owing to their psychoactive effects. Therefore, there is growing interest in development of synthetic compounds without cannabimimetic activity on the central nervous system. Ajulemic acid (AjA; 1′,1′-dimethylheptyl-tetrahydrocannabinol-11-oic acid) is a synthetic analogue of tetrahydrocannabinol, devoid of relevant psychotropic effects. 10 It is a potent anti-infl ammatory and analgesic agent in vivo. 10 First data in humans indicate that AjA is well tolerated and can reduce chronic neuropathic pain without signifi cant psychotropic effects in doses up to 80 mg/day. 11 Although, AjA may be able to activate CB1-mediated central effects by crossing the blood-brain barrier in mice, 12 the amount crossed seems not to be suffi cient to trigger psychoactivity in humans. 13 In addition to its affi nity for CB1 and CB2 receptors, cannabinoids, including AjA, are an emerging new class of molecules that can bind to, and activate, the peroxisome proliferatedactivated receptor-γ (PPAR-γ). [14] [15] [16] [17] PPAR-γ can be activated by some endocannabinoids and, in turn, PPAR-γ activation can modulate the endocannabinoid system, suggesting a reciprocal relationship. 18 Indeed, the agonist effects of endocannabinoids on PPAR-γ may contribute to the regulatory effects of endocannabinoids on infl ammation, and vasoactivity. 10 Moreover, recent evidence suggests a key role for PPAR-γ in fi brogenesis. Suppression of PPAR-γ may contribute to the uncontrolled activation of fi broblasts. 19 In fact, PPAR-γ and its natural occurring ligand 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), exert antifi brotic effects by suppressing collagen production and fi broblast activation in bleomycin-induced fi brosis. 20 21 
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Since systemic sclerosis (SSc) is an autoimmune disease in which vascular injury and infl ammation lead to progressive fi brosis of tissues, 22 the cannabinoid system and PPAR-γ have been suggested as potential therapeutic targets. Considering that therapeutic doses of AjA simultaneously activate PPAR-γ and the cannabinoid system without affecting the central nervous system, we hypothesised that AjA might also be effective in preventing fi brosis in experimental models of SSc.
MATERIAL AND METHODS

Animal models of experimental dermal fi brosis
To asses in vivo the potential role of AjA as an antifi brotic agent, three different animal models were analysed. AjA was evaluated in bleomycin-induced dermal fi brosis, characterised primarily by infl ammation, which typically occurs in the early phases of SSc. Skin fi brosis was induced in two groups of 6-week-old DBA/2J mice by local injection of bleomycin. Animals were treated with bleomycin alone (BLM group; n=8), bleomycin plus AjA 1 mg/kg/ day (BLM/AjA group; n=8) and 0.9% NaCl saline solution (control group; n=8). Briefl y, 100 μl of BLM dissolved in 0.9% NaCl at a concentration of 0.5 mg/ml was administered every other day, in well-defi ned areas (1 cm 2 ) of the upper back. 23 One group of BLM-challenged mice received orally AjA (JB Therapeutics, Newton, Massachusetts, USA) 1 mg/kg/day, dissolved in seed oil. Subcutaneous injections of 100 μl 0.9% NaCl were used as controls. After 21 days, animals were killed by cervical dislocation. The injected skin was removed and processed for analysis (see online supplementary text).
To test AjA on established fi brosis less dependent on infl ammatory mechanisms, a modifi ed model of bleomycin-induced dermal fi brosis was assessed, 24 in which mice were challenged with bleomycin for 6 weeks and AjA treatment started during the last 3 weeks of bleomycin injections. Briefl y, one group of mice was killed after receiving subcutaneous bleomycin injections for 6 weeks. The second group received bleomycin injections for 3 weeks followed by 0.9% NaCl injections for the next 3 weeks, to control for spontaneous regression of fi brosis. The third group was challenged with bleomycin for 6 weeks and was treated in parallel with AjA (1 mg/kg/day; oral administration) during the fi nal 3 weeks of bleomycin injections. Two groups of mice, receiving subcutaneous injections of 100 μl 0.9% NaCl for 3 weeks and 6 weeks, respectively, were used as controls. The injected skin was removed and processed for analysis (see online supplementary text).
To assess the effect of AjA in a different model of scleroderma fi brosis, a TGFβ-dependent model of dermal fi brosis was studied. Dermal fi brosis was induced in pathogen-free male C57BL/6 mice by intracutaneous injections of attenuated type V adenoviruses overexpressing a constitutively active TGFβ receptor I (AdTGFbRI) as described. 25 Three groups of mice were analysed. One group was treated in parallel orally with AjA (1 mg/ kg/day) for the last 4 weeks. Mice infected with attenuated type V adenoviruses encoding only for LacZ and sham treated with the solvent of AjA served as controls. Animals were killed after 8 weeks by cervical dislocation and back skin was removed for analysis (see online supplementary text).
Each treatment group consisted of eight mice. The local ethical committee approved all animal experiments.
Patients and fi broblast cultures
Dermal fi broblasts were obtained by a 5 mm punch biopsy from the leading edge of the affected skin on the forearm of fi ve patients affected by diffuse cutaneous SSc (dcSSc) in the fi brotic phase. All patients fulfi lled the criteria for dcSSc classifi cation proposed by LeRoy et al. 26 No patient was treated with an immunosuppressive agent or corticosteroids, nor were they taking cannabinoids for either recreational or therapeutic use at the time of biopsy (Table 1) . Control fi broblasts were obtained from skin biopsy specimens from fi ve healthy age-and sex-matched volunteers. Skin fi broblasts were expanded by outgrowth culture in Dulbecco's modifi ed Eagle's medium (DMEM; Gibco Invitrogen, Grand Island, NY USA) as described previously. 27 Fibroblasts from passages 3-6 were used for the experiments. All patients and healthy volunteers provided written informed consent using forms approved by the local institutional review boards.
Stimulation experiments
dcSSc and healthy dermal fi broblasts were cultured in DMEM containing 2.5% of fetal calf serum for 24 h before the experiments. Dermal fi broblasts were incubated with AjA (JB Therapeutics), dissolved in dimethyl sulphoxide at 0.1, 1, 5 and 10 μM concentrations for 24 h. Further experiments were performed by incubating dermal fi broblasts for 15 min before AjA treatment with the PPAR-γ irreversible antagonist GW9662 (Tocris Bioscience, Bristol, UK), at a concentration of 1 and 10 μM. (see online supplementary text).
Statistical analysis
Data are expressed as the mean±SD. Analysis of variance was used to compare multiple means, followed by the Student-Newman Keuls post hoc test (Sigma-StatV.3.5; Sigma Stat, Ashburn, Virginia, USA). p Values <0.05 were considered signifi cant.
RESULTS
Ajulemic acid prevented bleomycin-induced dermal fi brosis in vivo
To evaluate the potential of AjA as an antifi brotic agent in vivo, we tested its effi cacy in bleomycin-induced dermal fi brosis. Animals were treated with bleomycin alone (BLM group), bleomycin plus AjA 1 mg/kg/day (BLM/AjA group) and 0.9% NaCl saline solution (control group). After treatment, the BLM group and BLM/AjA group did not differ in body weight, and no other signs of toxicity of AjA such as ruffl ed fur or reduced activity were recorded.
Skin fi brosis was quantifi ed at day 21 by determining dermal thickness and hydroxyproline content of lesional skin. Skin from the BLM group showed dense accumulation of ECM in the dermis and accumulation of inflammatory cells in the deeper dermal layers and perivascular spaces. In addition, the subcutaneous fat tissue was largely replaced by connective tissue. (fi gure 1A) A twofold increase in dermal thickness was seen in mice injected 
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with BLM compared with controls (p<0.001). Oral administration of AjA (1 mg/kg/day) prevented development of skin fi brosis, and reduced skin thickness nearly to control levels (p<0.001 compared with mock treated mice) (fi gure 1B). Furthermore, in the BLM/AjA group the subcutaneous leucocyte infi ltration, the accumulation of ECM and the fat layer replacement were reduced (fi gure 1A).
Consistent with the histology, production of collagen, determined by quantifi cation of dermal hydroxyproline content, was reduced substantially in mice treated with AjA (fi gure 1C). In the BLM group, levels of hydroxyproline were more than twofold greater than in controls (p<0.001). AjA treatment (1 mg/kg/day) completely abrogated the collagen deposition induced by BLM (p<0.001).
Myofi broblasts, characterised by the cytoskeletal protein α-smooth muscle actin, are considered one of the major cellular mediators of fi brosis in SSc. In BLM-challenged mice the number of α-smooth muscle actin-positive spindle-shaped fi broblastic cells per high-power fi eld was increased twofold compared with controls (p<0.001). AjA treatment signifi cantly reduced the number of myofi broblasts in lesional skin up to 26±5% (mean±SD) (p<0.05) (fi gure 1D).
Ajulemic acid reduced progression of fi brosis in vivo
To assess whether AjA is effective in an in vivo model of dermal fi brosis that is largely independent of autoimmune and infl ammatory phenomena, we tested its effi cacy in the constitutively active TGFβ receptor type I mouse model (AdTGFbRI). AdTGFbRI mice are characterised by generalised dermal fi brosis and fi broblast-specifi c activation of TGFβ signalling. 23 After 8 weeks AdTGFbRI mice showed twofold increase in dermal thickness compared with AdLacZ control mice (p<0.05). Oral administration of AjA (1 mg/kg/day) for the last 4 weeks reduced development of skin thickness up to 30±6% (mean±SD) compared with AdTGFbRI mice (p<0.05) (Figure 2A,B) . AjA treatment (1 mg/kg/day) induced a mean reduction of 30±13% (mean±SD) in hydroxyproline content (p<0.05) (fi gure 2C). AjA treatment also signifi cantly reduced the number of myofi broblasts in lesional skin up to 26±3% (p<0.001) (fi gure 2D).
To further evaluate the effi cacy of AjA for the treatment of established fi brosis, we used a 6-week model of bleomycininduced dermal fi brosis. Consistent with previous studies, dermal thickness increased by 76±4% (mean±SD) (p<0.05 vs NaCl controls) after 6 weeks of treatment with bleomycin. To assess the effects of AjA, mice challenged with bleomycin for 6 weeks were treated in parallel with AjA (1 mg/kg/day) during the fi nal 3 weeks of bleomycin injections. Dermal thickness in mice treated with AjA for the last 3 weeks was reduced by 11±17% (mean±SD) compared with 6-week bleomycin-challenged mice (p<0.05). Furthermore, dermal thickness in mice treated with AjA did not differ signifi cantly from mice challenged with bleomycin for 3A,B) . Consistently, a twofold increase of levels of hydroxyproline was recorded in the 6-week bleomycin-challenged group compared with controls (p<0.001). AjA treatment for the last 3 weeks reduced collagen deposition by 10±8% (mean±SD) (p<0.05). Thus, AjA administration for the last 3 weeks of bleomycin challenge stopped further progression of fi brosis, but did not alter pre-existing ECM accumulation (fi gure 3C). The number of myofi broblasts after AjA treatment was signifi cantly reduced in lesional skin up to 25±16% (mean±SD) compared with bleomycin-challenged mice (p<0.05) (fi gure 3D).
Ajulemic acid inhibited collagen neosynthesis in dcSSc fi broblasts through PPAR-γ
To investigate whether AjA directly inhibits collagen synthesis in cultured fi broblasts, we quantifi ed the levels of procollagen type I propeptide (PIP) in supernatant from dcSSc and healthy cultured fi broblasts treated with AjA. AjA (0.1 to 10 μM) reduced the levels of PIP released from dcSSc fi broblasts in a dose-dependent manner. Maximal inhibition was observed at 10 μM concentration with a mean PIP reduction up to 60±7% (p<0.001) (fi gure 4). Similar results were seen in healthy dermal fi broblasts (data not shown).
AjA did not exert toxic effects on fi broblasts at the concentrations used. The metabolic activity measured by the MTT assay was not affected by treatment with AjA in concentrations up to 10 μM (data not shown).
To evaluate a PPAR-γ pathway dependency, dcSSc and healthy fi broblasts treated with AjA were preincubated with the highly selective PPAR-γ antagonist GW9662 (1-10 μM). The inhibitory effect of AjA on collagen production was completely prevented by GW9662 at 10 μM concentration (p<0.05) (fi gure 5A).
In addition, we analysed the effect of AjA on expression of the endogenous PPAR-γ ligand 15d-PGJ2. The levels of 15d-PGJ2 were reduced in supernatants of dcSSc fi broblasts compared with controls (p<0.001). However, incubation with AjA strongly increased the levels of 15d-PGJ2 in a dose-dependent manner (p<0.001) (fi gure 5B).
Further, we assessed PPAR-γ expression in dcSSc and healthy fi broblasts. The protein levels of PPAR-γ were reduced in dcSSc fi broblasts compared with healthy controls. However, treatment with AjA (5 μM and 10 μM) signifi cantly increased the expression of PPAR-γ in dcSSc fi broblasts (p<0.001) (fi gure 5C). AjA enhanced production of 15d-PGJ2 in systemic sclerosis (SSc) fi broblasts. Smaller amounts of the natural ligand of PPAR-γ, 15d-PGJ2, were found in the supernatant from diffuse cutaneous SSc (dcSSc) fi broblasts compared with the amounts from healthy controls. After AjA treatment supernatant levels of 15d-PGJ2 increased signifi cantly in a dose-dependent manner. Results are the mean±SD of fi ve separate experiments. #p<0.001 versus healthy fi broblasts; *p<0.001 vs untreated. (C) AjA increased PPAR-γ expression in dcSSc fi broblasts. dcSSc and healthy fi broblasts were treated with AjA at increasing concentrations (0.1, 1, 5 and 10 μM). At 24 h after treatment, cells were lysed and PPAR-γ protein levels were analysed by western blot (a) and densitometry (b). Lower PPAR-γ levels were seen in dcSSc fi broblasts than in healthy controls. After AjA treatment (5 μM and 10 μM) PPAR-γ protein expression increased signifi cantly. Results are the mean±SD of three separate experiments. #p<0.001 versus healthy fi broblasts; *p<0.001 versus untreated.
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(TGF) is considered a major profi brotic cytokine in orchestrating the uncontrolled activation of SSc fi broblasts with consequent overproduction of ECM. Moreover, in fi broblasts, TGFβ signalling is inversely related to PPAR-γ physiology function. 28 Since AjA suppressed collagen production through PPAR-γ activation, and in vivo reduced dermal fi brosis in the constitutively active TGFβ receptor type I mouse model (AdTGFbRI), we evaluated its ability to downregulate TGFβ in vitro. TGFβ concentrations in supernatants from dcSSc fi broblasts were signifi cantly higher than TGFβ concentrations in cultures from healthy controls (p<0.001). Upon incubation with AjA, a significant dose-dependent reduction in TGFβ concentrations (up to 50%) was seen in supernatants from dcSSc fi broblasts (p<0.001), with maximum suppression seen at 2 h (fi gure 6).
DISCUSSION
Results of experiments presented here indicate that AjA effi ciently prevents bleomycin-induced dermal fi brosis in mice. In addition, this cannabinoid can inhibit progression of ECM deposition in animal models of established skin fi brosis. In dcSSc fi broblasts, AjA inhibits collagen synthesis through activation of PPAR-γ.
Modulation of the CB1 and CB2 receptors limits skin fi brosis by reducing infl ammation. 6 7 Although the synthetic tetrahydrocannabinol analogue AjA is a weak ligand of the classical cannabinoids receptors CB1 and CB2, 10 we suggest that AjA may also act to reduce fi brosis directly through a PPAR-γ-mediated mechanism. Consistent with this notion are data which indicate that the high-affi nity cannabinoid receptor agonist WIN55, 212-2 exerts antifi brotic effects that are not mediated by the classic cannabinoid receptors. 8 9 A close relationship between the endocannabinoid system and PPAR-γ signalling has been postulated. 18 Accumulating evidence suggests that impaired expression and function of PPAR-γ is important in the pathogenesis of fi brosis in SSc. 28 Such diminished activity is counterbalanced by uncontrolled TGFβ signalling, thereby triggering fi brogenesis. 29 Cross-talk between these two mediators orchestrates the mechanisms of normal wound healing. 20 The activation of PPAR-γ by its natural ligands controls fibrotic responses. PGJ2 in a physiological condition increases during the resolution phase of wound healing by blocking fi broblast activation and collagen neosynthesis. 28 Upon chronic fibrogenic stimulation the expression and function of PPAR-γ are reduced, leading to unbalanced collagen neosynthesis driven by TGFβ signalling. Accordingly, PPAR-γ activation by PGJ2 results in a robust reduction of infl ammatory infi ltrates and progression of fi brosis in murine models of bleomycin-induced fi brosis. 21 Consistent with these fi ndings, we observed that the increased release of TGFβ is mirrored by a concomitant decrease of PPAR-γ. We demonstrate that AjA reduces release of TGFβ from dcSSc fi broblasts and that AjA can counteract the progression of fi brosis in vivo in an overactivated TGFβ pathway mouse model. Moreover, AjA also stimulates expression of the endogenous PPAR-γ ligand PGJ2. By inhibiting TGFβ and stimulating the release of PGJ2, AjA probably promotes PPAR-γ signalling in dcSSc fi broblasts.
We also show that oral administration of AjA attenuates markedly the dermal fi brosis induced in DBA/2J mice by bleomycin. AjA reduces fi broblast activation, ECM deposition, and subsequent dermal thickening. Bleomycin-induced dermal fi brosis is considered a reliable experimental model for SSc that refl ects the early stages of the disease, with increased deposition of collagen and other ECM components, migration of infl ammatory cells into the skin and atrophy of the adipose tissue. 30 It is still unclear why in SSc, atrophy of the fat tissue occurs, in favour of connective tissue replacement. However, recent data suggest that PPAR-γ might play a central role in regulating the balance between adipogenesis and fi brogenesis. 19 Accumulating evidence suggests that increased activation of PPAR-γ favours adipogenesis, whereas decreased PPAR-γ favours tissue fi brosis. According to this model, the downregulation of PPAR-γ seen in SSc would enhance recruitment of mesenchymal precursors, stimulate release of collagen from resident fi broblasts and inhibit adipogenic differentiation. 19 In accordance, reduction of PPAR-γ in Wnt-10b-transgenic mice suppresses adipogenesis while promoting reciprocal fi brogenesis. 31 Consistent with this hypothesis, AjA stimulates the differentiation of embryogenic fi broblastic 3T3 L1 cells into adipocytes, a process that is known to be mediated by PPAR-γ. 10 Based on these results, we suggest that AjA might exert its antifi brotic effects by restoring the defective PPAR-γ activation in dcSSc fi broblasts. We observed that AjA stimulates the expression of PPAR-γ in dcSSc fi broblasts, upregulating expression of its endogenous ligand 15d-PGJ2. We showed that activation of PPAR-γ is essential for the antifi brotic effects of AjA in vitro and that inhibition of PPAR-γ disrupts the inhibitory effects of AjA on collagen synthesis. In addition, treatment of bleomycin-challenged mice with AjA prevents fi brosis and also the characteristic atrophy of the subcutis. Results of the studies presented in this paper show that AjA reduces infi ltration of the dermis by infl ammatory cells. Since the mouse model of bleomycin-induced fi brosis is responsive to anti-infl ammatory drugs, 23 we might assume that anti-infl ammatory effects of AjA might also contribute to its antifi brotic activity in vivo. We also observed direct antifi brotic effects of AjA in in vivo models largely independent of infl ammation-for example, in mice overexpressing a constitutively active TGFβ receptor I. Moreover, in murine models of established fi brosis, we demonstrated that AjA reduces progression of fi brosis. However, treatment with AjA does not induce regression of preexisting fi brosis in these models.
In conclusion, we demonstrate that AjA exerts potent antifibrotic effects in vivo, which in vitro are mediated by PPAR-γ signalling. Cannabinoids and PPAR-γ agonists might be ideal drugs to target SSc since they can modulate fi brosis, infl ammation and vasodilatation, all of which are dysregulated in SSc. Our fi ndings have direct translational implications, because a proof-of-concept trial with AjA for the treatment of SSc is in preparation.
